Background: In addition to anti-citrullinated protein antibodies (ACPAs), antibodies targeting carbamylated (i.e., homocitrullinated) proteins (anti-CarP antibodies) have been described in rheumatoid arthritis (RA). However, the extent to which anti-CarP antibodies are truly distinct from ACPA remains unclear, and few studies have focused on specific autoantigens. Here, we examine cross-reactivity between ACPA and anti-CarP antibodies, in the context of the candidate autoantigen α-enolase.

Methods: Cross-reactivity was examined by immunoblotting of citrullinated and carbamylated proteins using purified ACPA; and by peptide absorption experiments, using the citrullinated α-enolase peptide CEP-1 and a homocitrulline-containing version (carb-CEP-1) in ELISA. The population-based case-control cohort EIRA (n = 2836 RA; 373 controls) was screened for reactivity with CEP-1 and carb-CEP-1, using the ISAC multiplex array. Associations between anti-CarP antibodies, smoking and genetic risk factors were analysed using unconditional logistic regression models. Differences in antibody levels were investigated using the Mann-Whitney U test.

Results: Affinity-purified ACPA was found to bind carbamylated proteins and homocitrulline-containing peptides, demonstrating definitive cross-reactivity between ACPA and anti-CarP antibodies. Anti-carb-CEP-1 reactivity in EIRA was almost exclusively confined to the CEP-1-positive subset, and this group of RA patients (21 %) displayed a particularly strong ACPA response with marked epitope spreading. The small RA subset (3 %) with homocitrulline reactivity in the absence of citrulline reactivity did not associate with smoking or risk genes, and importantly had significantly lower anti-carb-CEP-1 antibody levels.

Conclusion: Our data presented herein cast doubt on the specificity of anti-CarP antibodies in RA, which we posit may be a subset of cross-reactive ACPA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855497PMC
http://dx.doi.org/10.1186/s13075-016-1001-6DOI Listing

Publication Analysis

Top Keywords

anti-carp antibodies
24
antibodies
10
rheumatoid arthritis
8
anti-citrullinated protein
8
protein antibodies
8
cross-reactivity acpa
8
acpa anti-carp
8
carbamylated proteins
8
acpa
7
anti-carp
6

Similar Publications

The presence of anti-citrullinated peptide/protein antibodies (ACPAs), anti-carbamylated peptide/protein antibodies (anti-CarPs), and anti-acetylated peptide/protein antibodies (AAPAs), collectively termed as anti-modified peptide/protein antibodies (AMPAs), is a hallmark of rheumatoid arthritis. These autoantibodies play a crucial role in the complex autoimmune responses observed in patients. Understanding the interplay between them is essential for early diagnosis and effective management of the disease.

View Article and Find Full Text PDF

Clinical presentation and treatment response in ACPA-negative rheumatoid arthritis.

Joint Bone Spine

November 2024

UMR 1227 Lymphocytes B, Auto-immunité et Immunothérapies, University Brest, Inserm, CHU de Brest, Brest, France.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and potential extra-articular manifestations. This review compares the presentation and treatment response between anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA patients. The incidence of seronegative RA (rheumatoid factor [RF]-negative and ACPA-negative) has increased in recent decades, emphasizing the need for new diagnostic biomarkers.

View Article and Find Full Text PDF

Objective: Anti-citrullinated protein antibodies (ACPA) have been detected in sputum and saliva, indicating that anti-modified protein antibodies (AMPA) can be produced at mucosal sites in patients with rheumatoid arthritis (RA). However, the body's largest mucosal compartment, the gut, has not yet been examined. We therefore investigated the presence of several AMPA (ACPA, anti-carbamylated protein antibodies [anti-CarP], and anti-acetylated protein antibodies [AAPA]) at different mucosal sites, including the intestinal tract.

View Article and Find Full Text PDF

Background Rheumatoid arthritis (RA) is a widespread autoimmune disease affecting millions of people worldwide. The current markers include anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF), which are nonspecific and elevated in various conditions and do not have a prognostic value. They are also elevated in the later stages of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to evaluate the levels of anti-carbamylated protein (CarP) antibodies in patients with rheumatoid arthritis (RA) compared to non-RA patients and healthy controls, analyzing data from 259 subjects.
  • - Results showed that the anti-CarP antibody levels were significantly higher in RA patients (8.31 U/mL) than in non-RA patients (4.50 U/mL) and healthy controls (3.46 U/mL), with a sensitivity of 58.2% and specificity of 93.1% for diagnosing RA.
  • - The analysis highlighted that both anti-CarP and anti-CCP antibodies serve as independent risk factors for RA, with combined tests improving diagnostic sensitivity
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!